A5029251146- HIV Research and Treatment
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- HIV/AIDS Research and Interventions
- vaccines and immunoinformatics approaches
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- Immunodeficiency and Autoimmune Disorders
- Drug-Induced Adverse Reactions
- Reproductive System and Pregnancy
- Blood groups and transfusion
- Contact Dermatitis and Allergies
- Monoclonal and Polyclonal Antibodies Research
Instituto Nacional de Enfermedades Respiratorias
2019-2024
National Institute of Infectious Diseases
2017
Universidad Nacional Autónoma de México
2016
Mounting evidence indicates that HLA-mediated HIV evolution follows highly stereotypic pathways result in HLA-associated footprints at the population level. However, it is not known whether characteristic HLA frequency distributions different populations have resulted additional unique footprints.The phylogenetic dependency network model was applied to assess datasets of pol sequences from free plasma viruses and peripheral blood mononuclear cell (PBMC)-integrated proviruses an...
Abstract Associations between HLA class I alleles and HIV progression in populations exhibiting Amerindian Caucasian genetic admixture remain understudied. Using univariable multivariable analyses we evaluated associations with five clinical parameters 3,213 clade B-infected, ART-naïve individuals from Mexico Central America (MEX/CAM cohort). A Canadian cohort (HOMER, n = 1622) was used for comparison. As expected, allele frequencies MEX/CAM HOMER differed markedly. In MEX/CAM, 13 - , 24 B...
ABSTRACT The well-characterized association between HLA-B*27:05 and protection against HIV disease progression has been linked to immunodominant HLA-B*27:05-restricted CD8 + T-cell responses toward the conserved Gag KK10 (residues 263 272) polymerase (Pol) KY9 901 909) epitopes. We studied impact of 3 amino acid differences closely related HLA-B*27:02 on HIV-specific response hierarchy immune control HIV. Genetic epidemiological data indicate that both are associated with slower lower viral...
ABSTRACT Previous studies have demonstrated that effective cytotoxic T lymphocyte (CTL) responses drive the selection of escape mutations reduce viral replication capacity (VRC). Escape mutations, including those with reduced VRC, can be transmitted and accumulate in a population. Here we compared two antiretroviral therapy (ART)-naive HIV clade B-infected cohorts, Mexico Barbados, which most protective HLA alleles (HLA-B*27/57/58:01/81:01) are differentially expressed, at 8% 34%,...
HLA-B35 has consistently been associated with rapid HIV disease progression, particularly alleles of the Px group. As B35 is most prevalent HLA-B in Mexico, we investigated outcome relation to HLA expression a large cohort (n=976) Mexicans. Contrary previous studies, no impact on viral load or CD4 cell count was observed association PY/Px groups. However, differences specific alleles.
ABSTRACT HIV circumvents HLA class I-restricted CD8 + T-cell responses through selection of escape mutations that leave characteristic mutational “footprints,” also known as HLA-associated polymorphisms (HAPs), on sequences at the population level. While many footprints are universal across subtypes and human populations, others can be region specific a result unique immunogenetic background each host population. Using published probabilistic phylogenetically informed model, we compared HAPs...
Objective: Long-acting rilpivirine is a candidate for preexposure prophylaxis (PrEP) prevention of HIV-1 infection. However, resistance mutations at reverse transcriptase codon 138 (E138X) occur naturally in minority HIV-1-infected persons; particular those expressing human leukocyte antigen (HLA)-B*18 where transcriptase-E138X arises as an immune escape mutation. We investigate the global prevalence, B*18-linkage and replicative cost its regional implications PrEP. Methods: analyzed linked...
Background Therapeutic HIV vaccines may prove helpful to intensify antiretroviral treatment (ART) efficacy and be an integral part of future cure strategies. Methods We examined IFN-gamma ELISpot responses a panel 218 clade B consensus-based protease-reverse transcriptase peptides, designed mimic previously described predicted cytotoxic T lymphocyte epitopes overlapping drug resistance (DR) positions, that either included the consensus sequence or DR variant sequence, in 49 ART-naïve...
The nucleoside reverse transcriptase inhibitor abacavir (ABC) is used commonly to treat young children with HIV infection and a component of the fixed-dose-combination Triumeq®. ABC can trigger severe hypersensitivity reaction in people who are homozygous or heterozygous for HLA-B*57:01. Testing HLA-B*57:01 before initiation standard-of-care high-resource settings, but current tests costly difficult access resource-limited settings. To address these gaps, we developed an inexpensive...
In the context of infectious diseases, dynamic interplay between ever-changing host populations and viral biology demands a more flexible modeling approach than common fixed correlations. Embracing random-effects regression models allows for nuanced understanding intricate ecological evolutionary dynamics underlying complex phenomena, offering valuable insights into disease progression transmission patterns. this article, we employed to model an observed decreasing median plasma load (pVL)...
ABSTRACT Human leukocyte antigen (HLA) polymorphisms represent the strongest genetic modifier of HIV disease progression. Diverse HLA distributions can lead to distinct control landscapes at population level. We aimed describe allele and haplotype frequencies (linkage disequilibrium, LD), CCR5-Δ32 frequency, impact these variants on outcome. class I loci were typed 4-digit resolution, CCR5 determined in 402 clade B-infected, antiretroviral treatment-naïve individuals from Honduras. LD was...
Abstract Objective The nucleoside reverse transcriptase inhibitor abacavir is commonly used to treat young children with HIV infection. Abacavir can trigger a severe hypersensitivity reaction in people who are homozygous or heterozygous for HLA-B*57:01 . Testing prior initiation standard-of-care high-resource settings, but current tests too costly resource-limited settings. To address this gap, we developed an inexpensive, simple-to-use rapid assay detect Methods We designed and optimized...